Inderal and Turalio

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with pexidartinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 2C19. Concomitant administration of a single oral dose of pexidartinib (1800 mg) decreased the peak plasma concentration (Cmax) and systemic exposure (AUC) of omeprazole, a CYP450 2C19 substrate, by 37% and 17%, respectively, compared with omeprazole alone. MANAGEMENT: Caution is advised if pexidartinib is used concomitantly with drugs that are substrates of CYP450 2C1, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are CYP450 2C19 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C19-inducing activity may also be considered. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.

MONITOR: Coadministration with pexidartinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 2C19. Concomitant administration of a single oral dose of pexidartinib (1800 mg) decreased the peak plasma concentration (Cmax) and systemic exposure (AUC) of omeprazole, a CYP450 2C19 substrate, by 37% and 17%, respectively, compared with omeprazole alone.

MANAGEMENT: Caution is advised if pexidartinib is used concomitantly with drugs that are substrates of CYP450 2C1, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are CYP450 2C19 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2C19-inducing activity may also be considered.

Inderal

Generic Name: propranolol

Brand name: Inderal LA, Inderal XL, InnoPran XL, Inderal, Hemangeol, InnoPran XL

Synonyms: n.a.

What is Inderal?

Turalio

Generic Name: pexidartinib

Brand name: Turalio

Synonyms: n.a.

What is Turalio?